‘The digital lab’ can mean different things to different people, but the term broadly covers three types of laboratory systems: data management, automation and robotics, and artificial intelligence (AI) and machine learning (ML). Labs are looking to the potential cost and time savings these technologies can bring in an increasingly… Read More
Pioneer Group, Innovate UK, The Medical Research Council (MRC) and AstraZeneca have joined forces to deliver the AI in Health Accelerator 2024/2025 Programme. The Accelerator is designed to help entrepreneurs confidently market their AI-driven healthcare solutions and accelerate novel technology development time to market. The… Read More
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
When it comes to future developments in lab automation technology, the integration of artificial intelligence (AI) is the top area of anticipation for drug discovery labs. This is one of the key findings of the DDW Research & Consultancy 2025 Research Report Purchasing in Drug Discovery… Read More
DDW’s Megan Thomas speaks with Dr Raminderpal Singh ahead of his participation in the DDW ‘Concept to Cure’ track at SLAS2025: Curiosity and Lab Automation in Drug Discovery. SLAS as an organisation Having collaborated with numerous global organisations over the years, Dr Singh finds SLAS particularly forward-thinking. “You can see… Read More
DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Here, the focus is on technology, machine learning (ML) and artificial intelligence (AI). In a prediction piece written for Forbes, contributor Bernard Marr outlined five key technology trends for 2025 across multiple industries1. With… Read More
Results of an in vivo mouse colorectal cancer model study have shown a 60% life extension for Oxford Drug Design’s first-in-class approach against multiple tumours. The results follow previous in vivo validation of the therapeutic candidates and have led to… Read More
For the second year running, DDW is organising a series of seminars at SLAS International Conference and Exhibition. Based on the SLAS2025 theme of Curiosity Igniting Innovation, these will be available to visitors of SLAS2025 (25-29 January 2025, San Diego, USA). Lu Rahman outlines what’s on offer. The free DDW… Read More
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
NVIDIA has announced new partnerships with IQVIA, Illumina and Mayo Clinic, as well as Arc Institute, to accelerate drug discovery, enhance genomic research and pioneer advanced healthcare services. The projects include AI agents that can speed clinical trials by reducing administrative burden, AI models that learn from… Read More
This time last year DDW was reflecting upon the drug discovery and development sector’s push towards artificial intelligence (AI), in particular generative AI and how it could inform research. Within that article included the news of BenevolentAI’s disappointing results of its Phase II clinical trial of… Read More
This scientific note explores: The benefits of vendor-qualified protocols, incl. reducing start-up process. The three levels of automated library preparation readiness. How fully vendor-qualified libraries enable sequencing in as few as 5 days. The importance of choosing providers with NGS expertise. Case studies comparing custom vs. vendor-qualified solutions deployment. Read More
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
The US Food and Drug Administration (FDA) has issued the first guidance on the use of artificial intelligence (AI) for the development of drug and biological products. The draft guidance provides recommendations on the use of AI to support a regulatory decision about a drug or biological… Read More
Sentinal4D, a spinout company from The Institute of Cancer Research (ICR), London, has been announced to the public after closing its first round of funding. The new company aims to accelerate drug discovery and development to target drugs to patients, using patented artificial intelligence-driven methods for personalised… Read More
What were the trending topics of the year? Here, we run through DDW’s most read articles of 2024. 10: The future outlook for mRNA therapies In this article for the Spring 2024 issue, DDW Editor Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. 9: Key… Read More
